Hong Kong and London, UK – July 15th, 2024 – Farma Mondo Hong Kong Ltd., part of Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announce today the signing with Recordati UK Ltd. (a Recordati Rare Diseases Company) of an exclusive License and Distribution Agreement in Hong Kong for Qarziba® (dinutuximab beta), a cancer medicine used to treat neuroblastoma, a type of cancer of nerve cells, most often occurred in children younger than 5 years of age. Under the terms of the agreement, Farma Mondo Hong Kong becomes the local MAH and manages the commercial distribution of Qarziba in the Country.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented:
“We are proud to strengthen our partnership with Recordati Rare Diseases for the benefit of all young children with neuroblastoma in Hong Kong. Becoming a marketing authorisation holder is one of the services we offer our partners as a natural lifecycle evolution from the successful Named Patient Programme. This partnership underlines Farma Mondo’s commitment to widening access to lifesaving innovative medicines in emerging and established markets”.
Scott Pescatore, Executive Vice President Rare Disease at Recordati said:
“We are excited by the signature of the agreement for Qarziba® in Hong Kong. We are confident that the medical education activities conducted by Farma Mondo will help to improve the standard of treatment for children with neuroblastoma in Hong Kong”.
About Qarziba® Qarziba is a cancer medicine used to treat neuroblastoma, a cancer of nerve cells, occurred most often in patients younger than 5 years of age.
It is used in 2 groups of patients who have high-risk neuroblastoma (which has a high chance of coming back):
- patients who have had some improvement with previous treatments, which included blood stem cell transplantation (a transplant of blood-producing cells);
- patients whose neuroblastoma has not improved with other cancer treatments or has come back.
If the neuroblastoma has come back after previous treatment, it should be stabilised (stopped from getting worse) before treatment with Qarziba is started. Because the number of patients with neuroblastoma is low, the disease is considered ‘rare’, and Qarziba was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 November 2012. The medicine contains the active substance dinutuximab beta.
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
For more details, please visit https://farmamondo.com/
About Recordati
At Recordati Rare Diseases, we are “Focused on the few”, with a mission to reduce the impact of rare and devastating diseases by providing urgently needed therapies. Recordati Rare Diseases is focused on providing the most effective treatment for people living with rare diseases and has formed part of the Recordati Group since 2007.
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. Recordati operates in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.
For more information, visit the Recordati website https://www.recordati.com
